Treats human immunodeficiency virus type 1 (HIV-1) infection. ANDA 78064, held by Aurobindo Pharma. Efavirenz.
As of Nov 16, 2026, ANDA 78064 (Efavirenz), held by Aurobindo Pharma, was first approved by FDA on Dec 15, 2017, with 2 approved supplements and 0 published complete response letters.
Efavirenz capsules in combination with other antiretroviral agents are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg. Efavirenz is a non-nucleoside reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 15, 2017 | Original application | Approved |
| Jun 20, 2024 | Supplement 17Labeling · Standard review | Approved | None posted |
| Feb 4, 2020 | Supplement 14Labeling · Standard review | Approved | None posted |
| Dec 15, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters